Literature DB >> 7705922

Induction of apoptotic cell death in non-melanoma skin cancer by interferon-alpha.

J Rodríguez-Villanueva1, T J McDonnell.   

Abstract

Interferon-alpha (IFN-alpha) is a cytokine that is effective in the treatment of a variety of cancers, including non-melanoma skin cancers. The biologic responses of cells to IFN-alpha are pleiotropic and include growth suppression and immunomodulation. The potential direct effects of IFN-alpha on tumor cell populations are incompletely characterized. Our findings indicate that IFN-alpha can directly induce apoptosis (programmed cell death) in sensitive squamous cell skin cancer cell lines. Cell lines resistant to the cytotoxic effects of IFN-alpha showed no evidence of apoptosis induction. Transfection of IFN-alpha-sensitive cell lines with a bcl-2 expression vector conferred partial resistance to cell death induction by IFN-alpha. Our results indicate that the clinical efficacy of IFN-alpha may, in part, be related to the ability of this cytokine to induce apoptosis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7705922     DOI: 10.1002/ijc.2910610119

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  15 in total

1.  Type I interferons activate apoptosis in a Jurkat cell variant by caspase-dependent and independent mechanisms.

Authors:  Ana M Gamero; Ramesh Potla; Shuji Sakamoto; Darren P Baker; Robert Abraham; Andrew C Larner
Journal:  Cell Signal       Date:  2005-12-06       Impact factor: 4.315

2.  Ubiquitination of tissue transglutaminase is modulated by interferon alpha in human lung cancer cells.

Authors:  Carla Esposito; Monica Marra; Gaia Giuberti; Anna Maria D'Alessandro; Raffaele Porta; Anna Cozzolino; Michele Caraglia; Alberto Abbruzzese
Journal:  Biochem J       Date:  2003-02-15       Impact factor: 3.857

Review 3.  Interferons as inducers of apoptosis in malignant cells.

Authors:  Kevin P Kotredes; Ana M Gamero
Journal:  J Interferon Cytokine Res       Date:  2013-04       Impact factor: 2.607

4.  Multifaceted activities of type I interferon are revealed by a receptor antagonist.

Authors:  Doron Levin; William M Schneider; Hans-Heinrich Hoffmann; Ganit Yarden; Alberto Giovanni Busetto; Ohad Manor; Nanaocha Sharma; Charles M Rice; Gideon Schreiber
Journal:  Sci Signal       Date:  2014-05-27       Impact factor: 8.192

5.  Tyk2 tyrosine kinase expression is required for the maintenance of mitochondrial respiration in primary pro-B lymphocytes.

Authors:  Ramesh Potla; Thomas Koeck; Joanna Wegrzyn; Srujana Cherukuri; Kazuya Shimoda; Darren P Baker; Janice Wolfman; Sarah M Planchon; Christine Esposito; Brian Hoit; Jozef Dulak; Alan Wolfman; Dennis Stuehr; Andrew C Larner
Journal:  Mol Cell Biol       Date:  2006-09-18       Impact factor: 4.272

6.  Regression of basal cell carcinoma by intralesional interferon-alpha treatment is mediated by CD95 (Apo-1/Fas)-CD95 ligand-induced suicide.

Authors:  S A Buechner; M Wernli; T Harr; S Hahn; P Itin; P Erb
Journal:  J Clin Invest       Date:  1997-12-01       Impact factor: 14.808

Review 7.  Apoptosis and cell growth inhibition as antitumor effector functions of interferons.

Authors:  H Strander
Journal:  Med Oncol       Date:  2001       Impact factor: 3.064

8.  Anti-CD20-interferon-β fusion protein therapy of murine B-cell lymphomas.

Authors:  Kham R Trinh; Alex Vasuthasawat; Kristopher K Steward; Reiko E Yamada; John M Timmerman; Sherie L Morrison
Journal:  J Immunother       Date:  2013-06       Impact factor: 4.456

9.  Newcastle disease virus V protein is a determinant of host range restriction.

Authors:  Man-Seong Park; Adolfo García-Sastre; Jerome F Cros; Christopher F Basler; Peter Palese
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

10.  Antiproliferative Properties of Type I and Type II Interferon.

Authors:  Joseph Bekisz; Samuel Baron; Corey Balinsky; Angel Morrow; Kathryn C Zoon
Journal:  Pharmaceuticals (Basel)       Date:  2010-03-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.